Are you Dr. Meyer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3601 S 6th Ave
Tucson, AZ 85723Phone+1 520-629-4629Fax+1 520-629-1756
Summary
- Dr. Paul Meyer, MD is a board certified pathologist in Tucson, Arizona. He is currently licensed to practice medicine in Arizona, California, and Montana. He is affiliated with Tucson VA Medical Center.
Education & Training
University of Nebraska Medical Center College of MedicineFellowship, Hematopathology, 2008 - 2010
Loyola University Medical CenterResidency, Pathology-Anatomic and Clinical, 2004 - 2008
Pennsylvania State University College of MedicineClass of 2004
Certifications & Licensure
AZ State Medical License 2012 - Present
CA State Medical License 2011 - Present
NE State Medical License 2007 - 2026
MT State Medical License 2011 - 2013
NV State Medical License 2011 - 2013
WA State Medical License Active through 2013
ID State Medical License 2010 - 2012- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Hematopathology
- Join now to see all
Publications & Presentations
PubMed
- 701 citationsConcurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneNathalie A. Johnson, Graham W. Slack, Kerry J. Savage, Joseph M. Connors, Susana Ben-Neriah
Journal of Clinical Oncology. 2012-10-01 - 373 citationsImmunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With RituximabPaul N. Meyer, Kai Fu, Timothy C. Greiner, Lynette M. Smith, Jan Delabie
Journal of Clinical Oncology. 2011-01-10 - 109 citationsXp11.2 translocation renal cell carcinoma with very aggressive course in five adults.Paul N. Meyer, Joseph I. Clark, Robert C. Flanigan, Maria M. Picken
American Journal of Clinical Pathology. 2007-07-01
Press Mentions
Sirolimus (Rapamycin) for the Targeted Treatment of the Fibrotic Sequelae of Graves’ OrbitopathyFebruary 14th, 2019
